Multiple Sclerosis: all 3,524 studies
Page 31 of 36. Open to participants first (668), then studies with results posted, then the rest; newest registration first within each.
- Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis PatientsStatus unknownNCT01659593Not applicable
- Cognitive Evolution in Tysabri Treated Multiple Sclerosis PatientsCompletedNCT01658384
- FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of FampyraCompletedNCT01656148Phase 4
- Experimental Evaluation of Wheelchair-Mounted Robotic ArmsCompletedNCT01652352
- Prognosis Value of the Neuronal Damage in Early Multiple SclerosisStatus unknownNCT01651520Not applicable
- Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple SclerosisWithdrawnNCT01649050Phase 2
- MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)TerminatedNCT01647880Phase 2/3
- Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple SclerosisCompletedNCT01647321Not applicable
- Safety Study of GNbAC1 in Multiple Sclerosis PatientsCompletedNCT01639300Phase 2
- Evaluating Intervention Responsiveness in People With Multiple SclerosisCompletedNCT01632293Not applicable
- Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) StudyCompletedNCT01628315
- Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI StudyCompletedNCT01628276Not applicable
- Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in CombinationStatus unknownNCT01627938Phase 2
- Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active ControlCompletedNCT01626248
- Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced SubjectsStatus unknownNCT01624714Phase 1
- ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against InterferonWithdrawnNCT01621269Phase 4
- Relating Genetic and Environmental Risk Scores to Multiple Sclerosis SusceptibilityCompletedNCT01617395
- The Role of Exercise in Modifying Outcomes for People With Multiple SclerosisStatus unknownNCT01611987Not applicable
- Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy VolunteersCompletedNCT01610310Phase 1
- Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT01601119
- An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection DeviceCompletedNCT01601080
- Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.CompletedNCT01597297Phase 2
- Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple SclerosisCompletedNCT01596881
- A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker DiscoveryCompletedNCT01592552
- Evaluation of Brain Atrophy in CIS Patients on AvonexCompletedNCT01592474
- Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMSCompletedNCT01592097
- NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or SleepinessCompletedNCT01591551Phase 4
- Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting CellsCompletedNCT01587690
- Group Balance Training for People With Multiple SclerosisCompletedNCT01582126Not applicable
- Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple SclerosisStatus unknownNCT01576354Phase 2
- Examining the Effects of a Telehealth Self-management Intervention in Multiple SclerosisCompletedNCT01572714Not applicable
- The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.TerminatedNCT01567553
- Effects of Electromechanical Gait Trainer in Patients With Multiple SclerosisCompletedNCT01564511Not applicable
- Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)WithdrawnNCT01563900Not applicable
- MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and ColombiaCompletedNCT01556685Phase 4
- Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis PatientsWithdrawnNCT01555684Not applicable
- Assessing Relapse in Multiple Sclerosis (ARMS) QuestionnaireCompletedNCT01547351
- Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple SclerosisCompletedNCT01547234
- A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple SclerosisCompletedNCT01541618
- A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple SclerosisWithdrawnNCT01539395
- A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple SclerosisCompletedNCT01538355Not applicable
- Neurophysiological Study of Sativex in Multiple Sclerosis (MS) SpasticityCompletedNCT01538225Phase 3
- Fampridine Pregnancy Exposure RegistryTerminatedNCT01532154
- Self Help for Fatigue in Multiple SclerosisCompletedNCT01532037Not applicable
- Multiple Sclerosis and Progressive Resistance TrainingCompletedNCT01518660Not applicable
- Oral Testosterone for Fatigue in Male Multiple Sclerosis PatientsTerminatedNCT01516554Phase 2
- Pacing Activity Self-management for Patients With Multiple SclerosisCompletedNCT01512329Phase 2
- Occupational Therapy in Patients With Multiple SclerosisCompletedNCT01507636Not applicable
- Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy VolunteersCompletedNCT01500408Phase 1
- The Effects of Attention Retraining in MSCompletedNCT01492023
- Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple SclerosisCompletedNCT01491100
- Canadian Avonex PEN Productivity StudyCompletedNCT01489748
- Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedNCT01487096Phase 2
- Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsCompletedNCT01485003
- An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical PracticeCompletedNCT01480063
- Worms for Immune Regulation of Multiple SclerosisCompletedNCT01470521Phase 2
- A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.CompletedNCT01466322Phase 1
- Estriol Treatment in Multiple Sclerosis (MS): Effect on CognitionStatus unknownNCT01466114Phase 2
- Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled SamplesCompletedNCT01465087Not applicable
- Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Status unknownNCT01464905Phase 3
- Task-oriented Circuit Class Training in Multiple Sclerosis SubjectsCompletedNCT01464749Not applicable
- Glatiramer Acetate for Multiple Sclerosis With Autoimmune ComorbiditiesCompletedNCT01456416
- The Effects of Aerobics Training on Balance in Patients With Multiple SclerosisStatus unknownNCT01453868Early Phase 1
- Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple SclerosisWithdrawnNCT01453764Not applicable
- Neuroprotection With Phenytoin in Optic NeuritisCompletedNCT01451593Phase 2
- Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple SclerosisCompletedNCT01450488Phase 2
- Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)CompletedNCT01450124Phase 2
- T Cell Vaccination in Patients With Progressive Multiple SclerosisCompletedNCT01448252Phase 1/2
- Plasma Exchanges in Multiple Sclerosis (MS) RelapsesCompletedNCT01442233Phase 3
- Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying TherapiesCompletedNCT01442194
- Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)TerminatedNCT01440062Phase 2
- China Betaferon Adherence, Coping and Nurse Support StudyCompletedNCT01436838
- Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple SclerosisTerminatedNCT01435993Phase 1
- Robot-assisted Gait Training in Multiple Sclerosis SubjectsCompletedNCT01435694Not applicable
- Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisCompletedNCT01433497Phase 3
- Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)CompletedNCT01432704Phase 2/3
- Assessment of Repeat Ascending Doses of GSK2018682 in Healthy VolunteersCompletedNCT01431937Phase 1
- A Phase IIa Study of NT-KO-003 for Multiple SclerosisCompletedNCT01428726Phase 2
- [18F]PBR111 and Microglial Activation in Multiple SclerosisTerminatedNCT01428505Phase 2
- Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.CompletedNCT01424462Phase 1
- NOGO-A in Multiple Sclerosis FTIHTerminatedNCT01424423Phase 1
- Fingolimod -Response According to Coping - EvaluationCompletedNCT01420055Phase 4
- Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)CompletedNCT01419301Not applicable
- Metabolic Effects of a Green Tea Extract in Multiple Sclerosis PatientsCompletedNCT01417312Not applicable
- Impact of Vitamin A on Multiple Sclerosis (MS)Status unknownNCT01417273Phase 4
- Healthy Volunteer Study Using 3 Different Formulations of FirategrastCompletedNCT01416363Phase 1
- Betaferon® Regulatory Post-Marketing SurveillanceCompletedNCT01414816
- Core Stability Training in Multiple SclerosisCompletedNCT01414725Not applicable
- Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated SyndromeTerminatedNCT01413243Phase 2
- Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple SclerosisTerminatedNCT01411514Phase 4
- Impact of Vitamin A on Gene Expression, in Multiple Sclerosis PatientStatus unknownNCT01407211Phase 4
- Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.CompletedNCT01405872
- A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and TolerabilityWithdrawnNCT01404117Phase 2
- Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis PatientsCompletedNCT01399957
- Environmental and Genetic Risk Factors for Pediatric Multiple SclerosisCompletedNCT01396343
- GSK2018682 FTIH in Healthy VolunteersCompletedNCT01387217Phase 1
- Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative DiseasesCompletedNCT01384825
- Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)CompletedNCT01381354Phase 1
- Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis PatientsTerminatedNCT01380041
- Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple SclerosisCompletedNCT01377870Phase 1/2